The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

Tabula Rasa HealthCare

Status: Completed

Conditions: Behavioral and Psychiatric Symptoms of Dementia

Study type: Observational

Funder types: Industry

Identifiers

NCT03692182

AP-BPSD-001

Details and patient eligibility

About

The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.

Full description

Much national attention has been given to assessing and reducing the use of antipsychotics among nursing home residents, yet comparatively little attention has focused on antipsychotic use among older adults receiving care in community-based settings. The primary objective of this study is to determine the prevalence of antipsychotic use among a nationally representative sample of nursing home-eligible older adults in a community-based practice setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary objectives are focused on characterizing antipsychotic use within PACE and for these participants. Specifically, the investigator's secondary objectives are to describe patterns of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to identify clinically relevant drug-drug interactions involving antipsychotics.

Enrollment: 10,000 patients

Sex: All

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant enrolled in PACE contractually receiving pharmacy services from Tabula Rasa Healthcare CareKinesis Pharmacy (Tabula Rasa HealthCare) during the project time period (January 2017 through December 2017).

Exclusion criteria

• Participant with a diagnosis of bipolar disorder and/or schizophrenia, according to pharmacy records.

Trial design

10,000 participants in 1 patient group

Study group

Description:

Participants enrolled in PACE who received an antipsychotic medication.